A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
Early stage Hodgkin's disease: Ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP
Valeria Bonfante,Armando Santoro,Simonetta Viviani,Roberto Zucali,Liliana Devizzi,M. Zanini,John David Tesoro Tess,Pinuccia Valagussa,Alberto Banfi,Gianni Bonadonna +9 more
TL;DR: Present results confirm the usefulness of radiotherapy alone in favourable pathological stage IA and all other disease stages will require a different strategy that should consist of radi therapy combined with short-term effective regimens, such as ABVD or VBM to reduce the incidence of MOPP-associated gonadal dysfunction and leukaemogenesis.
Proceedings ArticleDOI
Abstract CT183: Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies
Giuseppe Curigliano,Hans Gelderblom,Nicolas Mach,Toshihiko Doi,Wai Meng David Tai,Patrick M. Forde,John Sarantopoulos,Philippe L. Bedard,Chia-Chi Lin,Stephen Hodi,Sofie Wilgenhof,Armando Santoro,Catherine Anne Sabatos-Peyton,Tyler Longmire,Kitty Wan,Panagiotis Nikolopoulos,Luigi Manenti,Aung Naing +17 more
TL;DR: The dose escalation results from a Ph I-Ib/II study of MBG453 ± spartalizumab in metastatic solid tumors show synergistic anti-tumor activity of TIM-3 and PD-1 co-blockade generally increased in a dose-proportional manner.
Journal ArticleDOI
Results of a First-In-Human Phase I Study of the Alk Inhibitor LDK378 in Advanced Solid Tumors
Alice T. Shaw,D.R. Camidge,Enriqueta Felip,Sunil Sharma,Daniel Shao-Weng Tan,Dong Wan Kim,T. De Pas,Johan Vansteenkiste,Armando Santoro,Geoffrey Liu,Meredith Goldwasser,D. Dai,Anthony Boral,Ranee Mehra +13 more
TL;DR: Daily oral LDK378 is well tolerated and the MTD was 750 mg/day, and striking activity was seen in ALK+ NSCLC pts treated at doses ≥400mg, who had previously progressed following crizotinib.
Journal ArticleDOI
Chemotherapy in the multidisciplinary approach to soft tissue sarcomas. EORTC Soft Tissue and Bone Sarcoma Group studies in perspective.
Jaap Verweij,A.T. van Oosterom,R. Somers,Armando Santoro,J. Rouëssé,J. Keizer,T. Tursz,Penella J. Woll,W. Steward,J. Buesa,P. Kerbrat,D. J. T. Wagener,V. Bramwell,D.G.T. Thomas,M. van Glabbeke,H. T. Mouridsen +15 more
Journal ArticleDOI
Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1–2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial
Corrado Tinterri,Damiano Gentile,Wolfgang Gatzemeier,Andrea Sagona,Erika Barbieri,Alberto Testori,Valentina Errico,Alberto Bottini,Emilia Marrazzo,Carla Dani,Beatrice Dozin,Luca Boni,Paolo Bruzzi,Bethania Fernandes,Davide Franceschini,R. Spoto,Rosalba Torrisi,Marta Scorsetti,Armando Santoro,Giuseppe Canavese,O. Custodero,Vito Leopoldo Troilo,Mario Taffurelli,Maria C. Cucchi,V Galluzzo,C. Cabula,R Cabula,Maria Grazia Lazzaretti,Francesco Caruso,G. Castiglione,Simona Grossi,Maria Saveria Tavoletta,Camilla Rossi,Annalisa Curcio,Daniel Friedman,Piero Fregatti,Carla Magni,Giovanni Tazzioli,Simona Papi,Riccardo Giovanazzi,Camelia Chifu,Rossella Bettini,Modestino Pezzella,Silvia Michieletto,Tania Saibene,Manuela Roncella,Matteo Ghilli,Andrea Sibilio,A. Cariello,Saverio Coiro,Giuseppe Falco,Emanuele Zarba Meli,Lucio Fortunato,Luigi Ciuffreda,Roberto Murgo,Claudio Battaglia,Luca Rubino,Nicoletta Biglia,Valentina Elisabetta Bounous,Francesca Rovera,Corrado Chiappa,Giovanni Paolo Pollini,Sara Mirandola,G. Meneghini,Francesco di Bartolo +64 more
TL;DR: The results do not support the use of routine ALND and the 3-year survival and relapse rates of T1–2 BC patients with one or two macrometastatic SLNs treated with SLNB only, and adjuvant therapy, were not inferior to those of patients treated with ALND.